Leukemia, Lymphocytic Clinical Trial
Official title:
A Phase 1b Pharmacokinetic-Pharmacodynamic-Pharmacogenomic Study of Enzastaurin in Patients With B-Cell Chronic Lymphocytic Leukemia (B-CLL)
Verified date | March 2009 |
Source | Eli Lilly and Company |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
The primary objective of this study is to see if enzastaurin affects the pGSK3 beta level in B-cell chronic lymphocytic leukemia (B-CLL) cells.
Status | Completed |
Enrollment | 18 |
Est. completion date | September 2008 |
Est. primary completion date | September 2008 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: Patients are eligible to be included in the study only if they meet all of the following criteria: 1. Patients with B-cell CLL as diagnosed by expression of CD19, CD5, and CD23 by flow cytometry. 2. Rai Stage III or IV disease or earlier stage disease with indications for therapy per NCI Working Group criteria (Cheson et al. 1996) 3. Absolute lymphocyte count > or = to 5,000/microliter, with a lymphocyte WBC differential of > or = to 70%. 4. Platelet count >20,000/microliter. 5. Adequate organ function, including the following: - Hepatic: bilirubin < or = to 1.5 times the upper limit of normal (x ULN); alkaline phosphatase (ALP), aspartate transaminase (AST), and alanine transaminase (ALT) < or = to 2.5 x ULN - Renal: serum creatinine < or = to 1.5 X ULN. Exclusion Criteria: Patients will be excluded from the study if they meet any of the following criteria: 1. Are unable to swallow tablets. 2. Are unable to discontinue use of carbamazepine, phenobarbital, and phenytoin. 3. Are pregnant or breastfeeding. 4. Have central nervous system (CNS) metastases (unless the patient has completed successful local therapy for CNS metastases and has been off of corticosteroids for at least 4 weeks before starting study therapy). 5. Have a serious concomitant systemic disorder (including active bacterial, fungal, or viral infection) that, in the opinion of the investigator, would compromise the patient's ability to adhere to the protocol. |
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Chicago | Illinois |
United States | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Duarte | California |
United States | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Houston | Texas |
United States | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | New York | New York |
Lead Sponsor | Collaborator |
---|---|
Eli Lilly and Company |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To characterize the inhibitory effects of enzastaurin on the pGSK3 beta level in B-CLL cells. | baseline, cycle 1, end of study | No | |
Secondary | Evaluation of activity of PKC beta in B-CLL cells | baseline, end of study | No | |
Secondary | Response rate | baseline to measured progressive disease | No | |
Secondary | Duration of response | time of response to progressive disease | No | |
Secondary | Time to progressive disease | baseline to measured progressive disease | No | |
Secondary | Safety | every cycle | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00270049 -
Epoetin Alfa for the Treatment of Anemia Resulting From Chronic Lymphocytic Leukemia
|
Phase 2 | |
Completed |
NCT00327678 -
Treatment of Acute Lymphoblastic Leukemia (ALL) in Younger Adults
|
Phase 3 | |
Completed |
NCT00313079 -
Monoclonal Antibody (mAb) 216 With Chemotherapy in Adult Relapsed or Refractory B-Lineage Acute Lymphoblastic Leukemia
|
Phase 1 | |
Completed |
NCT00025662 -
Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS
|
Phase 2 | |
Terminated |
NCT00306332 -
T-cell and B-cell Depletion in Allogeneic Peripheral Blood Stem Cell Transplantation
|
Phase 3 | |
Recruiting |
NCT06462248 -
Anti-CD19 Chimeric Antigen Receptor Modified T-cell (CAR-T) Therapy for Treatment of B-cell Hematological Malignancies
|
Phase 2 | |
Recruiting |
NCT05254743 -
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
|
Phase 3 | |
Completed |
NCT00034684 -
Study of Farnesyl Protein Transferase Inhibitor (FPTI) in Patients With Leukemia (Study P00701)
|
Phase 1/Phase 2 | |
Completed |
NCT00361140 -
Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT)
|
Phase 4 | |
Completed |
NCT00035022 -
Study of Intravenous BCX-1777 in Relapsed or Refractory Aggressive T-Cell Leukemias or Lymphomas
|
Phase 1/Phase 2 | |
Completed |
NCT01144793 -
Biomarker To Evaluate Protein Profiles of Neutropenic Fever/Infection With Acute or Chronic Leukemias
|
N/A | |
Active, not recruiting |
NCT00315419 -
Identifying Characteristics of Bone Marrow Failure Syndromes
|
N/A | |
Active, not recruiting |
NCT03792256 -
Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL)
|
Phase 1 |